Moein Moghimi is a Professor of Pharmaceutics and Nanomedicine (School of Pharmacy) and Affiliated Professor (Translational and Clinical Research Institute) at Newcastle University (UK); Adjoint Professor at the Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Denver Medical Center (USA); co-founder and advisory board member of S. M. Discovery Group Inc. (USA) and S. M. Discovery Group Ltd. (UK); Associate Editor of Molecular Therapy (The American Society of Gene and Cell Therapy, Cell Press); and Editor-in-Chief of the Journal of Nanotheranostics (Basel). His earlier appointments have included Professor and Chair in Pharmaceutics at the School of Medicine, Pharmacy and Health, Durham University, UK (2016- 2017); Full Affiliate Member/Professor at the Methodist Research Institute, Houston Methodist Hospital Systems, Houston, Texas, USA (2013-2017); Visiting Professor at Università Degli Studi Di Padova, Padova, Italy (2015); Professor of Nanomedicine (at the Department of Pharmacy), Professor of Pharmaceutical Nanotechology (at the NanoScience Center), and Founder/Director of the Center for Pharmaceutical Nanotechnology and Nanotoxiocology, University of Copenhagen, Denmark (2008-2016); and Honorary Professor of Nanomedicine at the Multidisciplinary Research Center, Shantou University, China (2008-2010).

Prof. Moghimi further serve on the editorial board of >20 international journals, including Advanced Drug Delivery Reviews , Journal of Controlled Release and Nanomedicine (UK) . Prof. Moghimi’s research is centred on fundamental and translational aspects of nanomedicine engineering and performance, with the overall goal of advancing fundamental understanding of biological barriers in relation to nanoparticle performance and safety, and within the context of precision medicine applicable to cancer, cardiovascular diseases, immune disorders, and disease of the central nervous system. As to date, Prof. Moghimi has published >300 research papers, reviews, book chapters, proceedings, and patents/patent applications. His work is highly cited in scientific literature (>22,500 citations as to date), and he is widely reported in general, local and professional press.